Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539478 | 0.99 | TAAR1 (0.45) | TAAR1GAAKDM4EL3MBTL1CYP3A4 | |
| SCHEMBL15075695 | 0.87 | SMN1; SMN2 (0.51) | KDM4ECYP3A4SLC9A1CYP2C19NOTUM | |
| SCHEMBL1397423 | 0.83 | ALDH1A1 (0.55) | TAAR1GAAKDM4EL3MBTL1CYP3A4 | |
| SCHEMBL4524615 | 0.82 | ALDH1A1 (0.58) | GAAKDM4EL3MBTL1HSD17B10POLB | |
| SCHEMBL15384274 | 0.82 | ALDH1A1 (0.58) | GAAKDM4EL3MBTL1HSD17B10POLB | |
| SCHEMBL2776207 | 0.80 | KDM4E (0.61) | TAAR1GAAKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL3643489 | 0.80 | KDM4E (0.61) | TAAR1GAAKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL3526351 | 0.79 | TTR (0.59) | TAAR1GAAKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL30949180 | 0.77 | TAAR1 (0.50) | TAAR1NOTUMALDH1A1 | |
| SCHEMBL17386600 | 0.77 | TAAR1 (0.56) | TAAR1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | TAAR1 992/4885GAA 1962/4885KDM4E 4024/4885 |
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | TAAR1 992/4885GAA 1962/4885KDM4E 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.